

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities of the Company.

Neither this announcement nor any copy thereof may be released into or distributed directly or indirectly in the United States or any other jurisdiction where such release or distribution might be unlawful.

This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), and may not be offered or sold in the United States unless registered under the U.S. Securities Act or pursuant to an exemption from, or in a transaction not subject to, registration under the U.S. Securities Act. The Company has no intention to register under the U.S. Securities Act any of the securities referred to herein or to conduct a public offering of securities in the United States.

3DMed

思路迪

3D Medicines Inc.

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1244)

COMPLETION OF PLACING OF NEW SHARES UNDER GENERAL MANDATE

Sole Overall Coordinator
J.P. Morgan Securities (Asia Pacific)
Limited

Placing Agent
J.P. Morgan Securities plc

J.P.Morgan

The Board are pleased to announce that all conditions of the Placing have been fulfilled, and completion of the Placing took place on July 21, 2023. Pursuant to the terms and conditions of the Placing Agreement, 2,150,000 Placing Shares have been successfully placed by the Placing Agent to not less than six Placées at the Placing Price of HK\$108.00 per Placing Share.

Reference is made to the announcement of 3D Medicines Inc. (the “**Company**”) dated July 14, 2023, in respect of the proposed placing of new Shares under the General Mandate (the “**Announcement**”). Unless otherwise stated, the terms used in this announcement shall have the same meaning as defined in the Announcement.

COMPLETION OF THE PLACING

The Board is pleased to announce that all conditions to the Placing have been fulfilled, and completion of the Placing took place on July 21, 2023. An aggregate of 2,150,000 Placing Shares have been placed by the Placing Agent to not less than six Placees at the Placing Price of HK\$108.00 per Placing Share pursuant to the terms and conditions of the Placing Agreement, representing approximately 0.83% of the total issued share capital of the Company as enlarged by the allotment and issue of the Placing Shares immediately upon completion of the Placing.

To the best of the Directors' knowledge, information and belief, having made all reasonable enquiries, the Placees and their respective ultimate beneficial owners are professional, institutional, or other investors who are Independent Third Parties. None of the Placees has become a substantial Shareholder upon completion of the Placing.

The net proceeds from the Placing (after deducting all applicable costs and expenses, including commissions and levies) amounted to approximately HK\$226.8 million. The Company intends to use the net proceeds for the purposes as disclosed in the paragraph headed "Reasons for the Placing and Use of Proceeds" in the Announcement.

SHAREHOLDING STRUCTURE OF THE COMPANY UPON COMPLETION OF THE PLACING

The shareholding structure of the Company immediately before and upon completion of the Placing are set out as follows:

	Immediately before the Placing		Immediately upon completion of the Placing	
	<i>Number of Shares held</i>	<i>Approximate % of total Shares in issue</i>	<i>Number of Shares held</i>	<i>Approximate % of total Shares in issue</i>
Dr. Gong Zhaolong and corporations controlled by him ⁽¹⁾	74,330,404	29.03%	74,330,404	28.79%
Simcere Pharmaceutical Group Limited	23,047,468	9.00%	23,047,468	8.93%
Shenzhen Efung Ruishi Investment Enterprise (Limited Partnership) ⁽²⁾	13,817,381	5.40%	13,817,381	5.35%
The Placees	–	–	2,150,000	0.83%
Other Shareholders	144,861,747	56.57%	144,861,747	56.10%
Total	256,057,000	100.00%	258,207,000	100.00%

Notes:

1. Dr. Gong Zhaolong controls 74,330,404 Shares through (a) Dragon Prosper Holdings Limited, which holds 35,992,364 Shares and is wholly-owned by Dr. Gong Zhaolong, and (b) Immunal Medixin US Limited, Immunal Medixin Cino L. Limited and Immunal Medixin Cino Limited, which hold in aggregate 38,338,040 Shares and are share incentive platforms managed by KASTLE LIMITED as trustee who, in accordance with the trust deed, acts in accordance with Dr. Gong Zhaolong's instructions when exercising voting rights attached to the Shares held by itself.
2. Shenzhen Efung Ruishi Investment Enterprise (Limited Partnership) ("**Shenzhen Efung**") is interested in our Shares through its affiliate, Shanghai Zhenlu Enterprise Management Consulting Partnership (Limited Partnership). Shenzhen Efung's executive partner is Shenzhen Efung Investment Management Enterprise (L.P.), which is in turn owned as to 51% by Shenzhen Efung Holding Co., Ltd. ("**Shenzhen Efung Holding**"). Shenzhen Efung Holding is in turn owned as to 54% and 23% by Mr. Zhu Jinqiao and Mr. Zhu Pai respectively. Mr. Zhu Jinqiao and Mr. Zhu Pai shall act in concert in relation to the exercising of their voting rights in Shenzhen Efung Holding. Accordingly, each of Shenzhen Efung, Shanghai Zhenlu Enterprise Management Consulting Partnership (Limited Partnership), Shenzhen Efung Investment Management Enterprise (L.P.), Shenzhen Efung Holding, Mr. Zhu Pai and Mr. Zhu Jinqiao are deemed to be interested in the Shares held by Shanghai Zhenlu Enterprise Management Consulting Partnership (Limited Partnership).

RISK WARNING

Due to the high-tech, high-risk and high value-added characteristics of pharmaceutical products, there are substantial risks and uncertainties in the process of drug research, development and commercialization. These many stages make it susceptible to uncertainties and therefore, investors are advised to make cautious decisions and pay careful attention to investment risks. The Company will actively pursue the described research and development project and fulfill its information disclosure obligations in a timely manner for subsequent progress in strict compliance with relevant regulations.

By Order of the Board

3D Medicines Inc.

Dr. Gong Zhaolong

Chairman of the Board and Executive Director

Hong Kong, July 21, 2023

As at the date of this announcement, the Board of Directors of the Company comprises Dr. GONG Zhaolong as executive Director, Mr. ZHU Pai, Mr. ZHOU Feng and Ms. CHEN Yawen as non-executive Directors, and Dr. LI Jin, Dr. LIN Tat Pang and Mr. LIU Xinguang as independent non-executive Directors.